Dyadic Logo Current.jpg
Dyadic to Present at Upcoming Events
May 03, 2021 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and...
Dyadic Logo Current.jpg
Dyadic International Hosting a Fireside Chat on “The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges”
April 22, 2021 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., April 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on developing and...
Dyadic Logo Current.jpg
UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial
March 29, 2021 08:30 ET | Dyadic International, Inc.
Advancing Dyadic’s proprietary owned COVID-19 vaccine candidate, DYAI-100, towards first-in-human Phase 1 clinical trial Engaged CR2O, a contract research organization, to manage and support further...
Dyadic Logo Current.jpg
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
March 23, 2021 09:00 ET | Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
Dyadic Logo Current.jpg
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
March 22, 2021 21:00 ET | Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
Dyadic Logo Current.jpg
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
March 22, 2021 08:30 ET | Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
Dyadic Logo Current.jpg
Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100
March 18, 2021 08:30 ET | Dyadic International, Inc.
Israel Institute for Biological Research (IIBR) reports successful challenge studies using human ACE2 transgenic mice vaccinated with SARS-CoV-2-S-RBD vaccine candidate manufactured from...
106 COVID VARIANTS IDENTIFIED IN 12 U.S. STATES
March 09, 2021 12:19 ET | MAKO Medical
Raleigh, North Carolina, March 09, 2021 (GLOBE NEWSWIRE) -- RALEIGH, NORTH CAROLINA [March 9, 2021]— MAKO Medical Laboratories, a national reference laboratory and leader in COVID-19 testing,...
MAKO MEDICAL RELEASES LATEST COVID-19 VARIANT DATA
February 16, 2021 11:39 ET | MAKO Medical
Raleigh, North Carolina, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MAKO Medical Laboratories, a national reference laboratory and leader in COVID-19 testing, released new information regarding the company's...